Candel Therapeutics Inc (NASDAQ:CADL) has a beta value of -0.92 and has seen 1.2 million shares traded in the last trading session. The company, currently valued at $265.81M, closed the last trade at $5.39 per share which meant it gained $0.38 on the day or 7.68% during that session. The CADL stock price is -170.87% off its 52-week high price of $14.60 and 29.68% above the 52-week low of $3.79.
The consensus among analysts is that Candel Therapeutics Inc (CADL) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
Candel Therapeutics Inc (NASDAQ:CADL) trade information
Sporting 7.68% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CADL stock price touched $5.39 or saw a rise of 3.58%. Year-to-date, Candel Therapeutics Inc shares have moved -37.85%, while the 5-day performance has seen it change 17.54%. Over the past 30 days, the shares of Candel Therapeutics Inc (NASDAQ:CADL) have changed 8.55%.
Candel Therapeutics Inc (CADL) estimates and forecasts
The company’s shares have gained 5.99% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -43.86% over the past 5 years. Earnings growth for 2025 is a modest 40.03% while over the next 5 years, the company’s earnings are expected to increase by 28.77%.
CADL Dividends
Candel Therapeutics Inc is expected to release its next earnings report in June this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Candel Therapeutics Inc (NASDAQ:CADL)’s Major holders
The top two institutional holders are NORTHPOND VENTURES, LLC with over 1.94 million shares worth more than $12.0 million. As of 2024-06-30, NORTHPOND VENTURES, LLC held 6.477% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 0.82 million shares as of 2024-06-30. The firm’s total holdings are worth over $5.1 million and represent 2.7548% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Select Portfolios-Biotechnology Portfolio and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 11.25% shares in the company for having 5.54 shares of worth $29.92 million while later fund manager owns 866.65 shares of worth $4.68 million as of Dec 31, 2024 , which makes it owner of about 1.76% of company’s outstanding stock.
